Jade Biosciences Announces 2026 Strategic Plans Including JADE101 Phase 2 Trial Initiation for IgA Nephropathy, Interim Phase 1 Data Release, and Advancement of JADE301 Antibody Program Toward First-in-Human Study

Reuters · 5d ago

Please log in to view news